Compare Incyte Corporation (INCY) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Clear Secure Inc — how do they compare? Incyte Corporation trades at $120.58 (market cap $24.54B), while Clear Secure Inc trades at $46.8 (market cap $4.98B). The key difference: Incyte Corporation is far larger — about 4.9× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | YOU | |
|---|---|---|
Market Cap | $24.54B | $4.98B |
Sector | Health | Technology |
52-Week High | $129.93 | $62.36 |
52-Week Low | $81.61 | $29.61 |
Enterprise Value | $20.04B | $4.13B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
CLEAR Secure (YOU) trades at $46.98, down 8.26% in 24 hours, reflecting recent bearish pressure but holding above key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.49 per share, revenue growth to $1.0 billion in 2026, and robust profitability margins. Technical indicators are mixed, with moving averages bearish but oscillators like RSI suggesting potential oversold conditions. Recent news highlights expansion in identity verification services and corporate memberships.
Outlook is cautiously optimistic due to earnings beats and growth initiatives, but risks include high valuation multiples and market volatility. Analysts are divided with a near-even buy/hold split, indicating balanced sentiment. Investors should weigh strong operational cash flow against competitive pressures in the identity security sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
